Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) is a key enzyme in the folate biosynthesis pathway of the malaria parasite. It catalyzes two sequential reactions essential for DNA synthesis and cell proliferation: reduction of dihydrofolate to tetrahydrofolate (DHFR activity) and methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) using methylene tetrahydrofolate as a cofactor. Unlike humans, where DHFR and TS are separate proteins, P. falciparum expresses these activities on a single polypeptide chain, making PfDHFR-TS bifunctional. It is a validated antimalarial drug target, but resistance has emerged.
Inhibition of dihydrofolate reductase and thymidylate synthase activities, leading to disruption of DNA synthesis and cell proliferation in Plasmodium falciparum.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase (PfDHFR-TS).